Federal Register / Vol. 86, No. 19 / Monday, February 1, 2021 / Notices 7725 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

CE21–004: Research Grants for 

Preventing Violence and Violence 

Related Injury. 

Date: May 25–26, 2021. 

Time: 8:30 a.m.–5:00 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Mikel Walters, Ph.D., Scientific Review 

Officer, National Center for Injury 

Prevention and Control, CDC, 4770 

Buford Highway NE, Mailstop F–63, 

Atlanta, Georgia 30341, Telephone (404) 

639–0913, MWalters@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–02051 Filed 1–29–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

CE21–005, The CDC National Centers of 

Excellence in Youth Violence 

Prevention (YVPCs): Rigorous 

Evaluation of Prevention Strategies to 

Prevent and Reduce Community Rates 

of Youth Violence. 

Date: June 22–24, 2021. 

Time: 8:30 a.m.–5:00 p.m., EDT. 

Place: Web Conference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Mikel Walters, Ph.D., Scientific Review 

Officer, National Center for Injury 

Prevention and Control, CDC, 4770 

Buford Highway NE, Mailstop F–63, 

Atlanta, Georgia 30341, Telephone (404) 

639–0913, MWalters@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–02054 Filed 1–29–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 86 FR 6336–6340, dated 

January 20, 2021) is amended to reflect 

the Order of Succession for the Centers 

for Disease Control and Prevention. 

Section C–C, Order of Succession, is 

hereby amended as follows: 

Delete in its entirety Section C–C, 

Order of Succession, and insert the 

following: 

During the absence or disability of the 

Director, Centers for Disease Control 

and Prevention (CDC), or in the event of 

a vacancy in that office, the first official 

listed below who is available shall act 

as Director, except that during a 

planned period of absence, the Director 

may specify a different order of 

succession: 

1. Principal Deputy Director 

2. Chief Medical Officer 

3. Deputy Director for Public Health 

Service and Implementation 

Science 

4. Deputy Director for Infectious 

Diseases 

5. Deputy Director for Public Health 

Science and Surveillance 

6. Deputy Director for Non-Infectious 

Diseases 

7. Director, National Institute for 

Occupational Safety and Health 

Sherri Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2021–02093 Filed 1–29–21; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and